Video Experimental Relacionado

Updated: Nov 29, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

Resistencia adquirida a la inhibición de la IDH a través de mutaciones de la interfaz dimérica trans o cis

Andrew M Intlekofer1,2,3,4, Alan H Shih1,2,4,5, Bo Wang1,2,6

  • 1Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Nature
|June 29, 2018
PubMed
Resumen

Las mutaciones somáticas en la isocitrato deshidrogenasa 2 (IDH2) conducen a la leucemia mieloide aguda (LMA). Pueden surgir nuevas mutaciones de IDH2, causando resistencia a terapias dirigidas como el enasidenib al permitir la producción de 2-hidroxiglutarato (2HG).

Más Videos Relacionados

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.9K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.1K

Videos de Conceptos Relacionados

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K